These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 234291

  • 21. Risks of BCG intralesional therapy: an experience with melanoma.
    Robinson JC.
    J Surg Oncol; 1977; 9(6):587-93. PubMed ID: 145518
    [Abstract] [Full Text] [Related]

  • 22. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH, Deutschmann EM, Schultheis W, Deicher H.
    Dev Biol Stand; 1977; 38():537-40. PubMed ID: 344106
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA, Nika B, Hsia WC, Crispen R, Sabet TY, Gupta TK.
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [Abstract] [Full Text] [Related]

  • 24. Immunology and cutaneous malignant melanoma.
    Sober AJ.
    Int J Dermatol; 1976 Mar; 15(1):1-18. PubMed ID: 1107238
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS, Peters M.
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pott's disease following BCG therapy of melanoma.
    Strausser JL, Quindlen EA.
    Cancer; 1981 Sep 01; 48(5):1154-6. PubMed ID: 7272949
    [Abstract] [Full Text] [Related]

  • 29. Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.
    Briggs PC, Heckler FR.
    Plast Reconstr Surg; 1988 Jun 01; 81(6):952-3. PubMed ID: 3375359
    [Abstract] [Full Text] [Related]

  • 30. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.
    Silverstein MJ, DeKernion J, Morton DL.
    JAMA; 1974 Aug 05; 229(6):688. PubMed ID: 4408302
    [No Abstract] [Full Text] [Related]

  • 31. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Aug 05; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
    Balzarini GP, Cascinelli N, Fontana V, Veronesi U.
    Tumori; 1974 Aug 05; 60(4):345-52. PubMed ID: 4439501
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Successful transurethral intralesional BCG therapy of a bladder melanoma.
    deKernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL.
    Cancer; 1975 Nov 05; 36(5):1662-7. PubMed ID: 1192356
    [Abstract] [Full Text] [Related]

  • 39. [Immunotherapy with BCG as coadjuvant in the management of malignant melanomas].
    Céspedes de Gómez MM, Aguilar Velázquez G, Valles de Cortés Y.
    Alergia; 1980 Apr 05; 27(2):69-86. PubMed ID: 7416444
    [No Abstract] [Full Text] [Related]

  • 40. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    Hedley DW, McElwain TJ, Currie GA.
    Eur J Cancer (1965); 1977 Oct 05; 13(10):1169-73. PubMed ID: 923614
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.